ReviewSignal transduction and targeted therapy2024
Cold and hot tumors: from molecular mechanisms to targeted therapy.
Review in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 444 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
444 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Advancements in immunotherapy for oropharyngeal cancer: Current landscape and future prospects.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026Pooled it
- Efficacy and safety of sequential versus concurrent administration of immune checkpoint inhibitors with radiotherapy in solid tumors: a systematic review and network meta-analysis.Cancer immunology, immunotherapy : CII · 2026Pooled it
- Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.Journal for immunotherapy of cancer · 2026Trial
- Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.JAMA oncology · 2026Trial
- Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.Journal for immunotherapy of cancer · 2026Trial
- First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.JAMA oncology · 2026Trial
- Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.Oncoimmunology · 2026Article
- Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models.Oncoimmunology · 2026Article
- xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.Cancer biology & therapy · 2026Article
- Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.Oncoimmunology · 2026Article
- ZIF-8 nanoplatform coordinating ZnInternational journal of pharmaceutics: X · 2026Article
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- Mitochondria-targeted photodynamic nanoparticles boost antitumor immunity by suppressing mitophagy in osteosarcoma.Bioactive materials · 2026Article
- Metal-phenolic nanocapsules enable a self-amplifying cuproptosis-STING cascade for synergistic cancer immunotherapy.Bioactive materials · 2026Article
- Carrier-free nanomodulators reprogramming acetate metabolism for cancer photo-immunotherapy via c-Myc inhibition-induced closed-loop regulatory circuit.Materials today. Bio · 2026Article
- Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.Materials today. Bio · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
384 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which has shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment in cancer therapy, only a minority of patients exhibit a positive response to it. In patients with solid tumors, those who respond well to ICB treatment typically demonstrate an active immune profile referred to as the "hot" (immune-inflamed) phenotype. On the other hand, non-responsive patients may exhibit a distinct "cold" (immune-desert) phenotype, differing from the features of "hot" tumors. Additionally, there is a more nuanced "excluded" immune phenotype, positioned between the "cold" and "hot" categories, known as the immune "excluded" type. Effective differentiation between "cold" and "hot" tumors, and understanding tumor intrinsic factors, immune characteristics, TME, and external factors are critical for predicting tumor response and treatment results. It is widely accepted that ICB therapy exerts a more profound effect on "hot" tumors, with limited efficacy against "cold" or "altered" tumors, necessitating combinations with other therapeutic modalities to enhance immune cell infiltration into tumor tissue and convert "cold" or "altered" tumors into "hot" ones. Therefore, aligning with the traits of "cold" and "hot" tumors, this review systematically delineates the respective immune characteristics, influencing factors, and extensively discusses varied treatment approaches and drug targets based on "cold" and "hot" tumors to assess clinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.